SCHEMBL21292841

SCHEMBL21292841

CC1(c2ccc(N3CCOCC3)cc2)N[C@@H](C(=O)O)Cc2c1[nH]c1ccccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.59
KMT2A Q03164 5/20 0.52
ALDH1A1 P00352 4/20 0.43
TSHR P16473 2/20 0.43
MMP3 P08254 1/20 0.42
MMP8 P22894 1/20 0.42
MEN1 O00255 3/20 0.42
OPRM1 P35372 2/20 0.42
OGFRL1 Q5TC84 2/20 0.42
SSTR3 P32745 2/20 0.41
KCNH2 Q12809 1/20 0.41
MAPT P10636 4/20 0.40
HPGD P15428 2/20 0.40
KIF11 P52732 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3850930 0.85 KDM4E (0.75) KDM4EKMT2AALDH1A1TSHRMEN1
SCHEMBL7811485 0.83 KDM4E (0.67) KDM4EKMT2AALDH1A1TSHRMEN1
SCHEMBL3482945 0.79 KDM4E (0.62) KDM4EKMT2AALDH1A1TSHRMEN1
SCHEMBL7712450 0.78 KDM4E (0.61) KDM4EKMT2AALDH1A1TSHRMEN1
SCHEMBL7687272 0.78 KDM4E (0.61) KDM4EKMT2AALDH1A1TSHRMEN1
SCHEMBL1922261 0.78 KDM4E (0.61) KDM4EKMT2AALDH1A1TSHRMEN1
SCHEMBL1420044 0.78 KDM4E (0.61) KDM4EKMT2AALDH1A1TSHRMEN1
SCHEMBL7706563 0.78 KDM4E (0.61) KDM4EKMT2AALDH1A1TSHRMEN1
Hydrochloric Acid SCHEMBL1894628 0.78 KDM4E (0.60) KDM4EKMT2AALDH1A1TSHRMEN1
Hydrochloric Acid SCHEMBL1784781 0.78 KDM4E (0.60) KDM4EKMT2AALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759075-B1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE FERRO THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039846-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 KDM4E 2312/4885KMT2A 2510/4885ALDH1A1 1254/4885
US-20190263802-A1 COMPOUNDS AND METHOD OF USE AIFM2, GPX4, GPX1 KDM4E 2426/4885KMT2A 2475/4885ALDH1A1 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.